Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 4, Pages 1873-1888
Publisher
American Chemical Society (ACS)
Online
2021-02-16
DOI
10.1021/acs.jmedchem.0c01917
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The β-secretase BACE1 in Alzheimer’s disease
- (2020) Harald Hampel et al. BIOLOGICAL PSYCHIATRY
- Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
- (2020) Gerald Novak et al. Alzheimers Research & Therapy
- Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
- (2020) Ivan Alić et al. MOLECULAR PSYCHIATRY
- Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)
- (2020) Frederik Rombouts et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- New Evolutions in the BACE1 Inhibitor Field from 2014 to 2018
- (2019) Chien-Chi Hsiao et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
- (2019) David Henley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trifluoromethyl Dihydrothiazine‐Based β‐Secretase (BACE1) Inhibitors with Robust Central β‐Amyloid Reduction and Minimal Covalent Binding Burden
- (2019) Kosuke Anan et al. ChemMedChem
- Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose
- (2019) Genta Tadano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
- (2019) Alette M. Wessels et al. JAMA Neurology
- Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization
- (2018) Kenji Nakahara et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain
- (2018) Kouki Fuchino et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
- (2018) Ulf Neumann et al. EMBO Molecular Medicine
- Synthesis of a 6-CF3-Substituted 2-Amino-dihydro-1,3-thiazine β-Secretase Inhibitor by N,N-Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization
- (2018) Takuya Oguma et al. JOURNAL OF ORGANIC CHEMISTRY
- AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
- (2016) Susanna Eketjäll et al. JOURNAL OF ALZHEIMERS DISEASE
- Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease
- (2016) Jack D. Scott et al. JOURNAL OF MEDICINAL CHEMISTRY
- Defeating Alzheimer's disease and other dementias: a priority for European science and society
- (2016) Bengt Winblad et al. LANCET NEUROLOGY
- Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate
- (2016) Ingrid C. Rulifson et al. PLoS One
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS -amyloid in animal models and in Alzheimers disease patients
- (2016) M. E. Kennedy et al. Science Translational Medicine
- BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
- (2016) Soraia Barão et al. TRENDS IN NEUROSCIENCES
- Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
- (2016) Derya R. Shimshek et al. Scientific Reports
- CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
- (2015) Zoran Rankovic JOURNAL OF MEDICINAL CHEMISTRY
- The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A Pharmacodynamic Responses in Mice, Dogs, and Humans
- (2015) P. C. May et al. JOURNAL OF NEUROSCIENCE
- The evolution of amidine-based brain penetrant BACE1 inhibitors
- (2014) Daniel Oehlrich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
- (2014) Arun K. Ghosh et al. CHEMICAL SOCIETY REVIEWS
- Targeting the β secretase BACE1 for Alzheimer's disease therapy
- (2014) Riqiang Yan et al. LANCET NEUROLOGY
- Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat
- (2014) Mark R. Fielden et al. TOXICOLOGIC PATHOLOGY
- BACE1 inhibitors: A head group scan on a series of amides
- (2013) Thomas J. Woltering et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease
- (2013) Hans Hilpert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer’s Disease
- (2013) Jing Yuan et al. JOURNAL OF MEDICINAL CHEMISTRY
- BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells
- (2013) L. Rochin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs
- (2012) Richard A. Thompson et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks
- (2012) Suvi T. M. Orr et al. JOURNAL OF MEDICINAL CHEMISTRY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
- (2011) Daria Esterházy et al. Cell Metabolism
- Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
- (2011) Antonia F. Stepan et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Robust Central Reduction of Amyloid- in Humans with an Orally Available, Non-Peptidic -Secretase Inhibitor
- (2011) P. C. May et al. JOURNAL OF NEUROSCIENCE
- Synthesis and Applications oftert-Butanesulfinamide
- (2010) MaryAnn T. Robak et al. CHEMICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search